A review of findings from a five-person committee is being sent to the ADA board for action, STAT has learned, but it appears unlikely to quiet the controversy.
Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill.